title: Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
abstract: Extranodal natural killer/T-cell lymphoma (NKTCL) has aggressive behaviors and poor clinical outcomes. A monomethyl auristatin E-conjugated anti-CD30 antibody (brentuximab vedotin) was recently introduced to treat CD30-positive lymphomas. Thus we investigated the clinicopathological features and prognostic implications of CD30 expression in 72 patients with NKTCL. CD30-positive cases, defined as cases with CD30 expression in more than 1%, 5% and 25% of tumor cells as cut-off values (COVs), accounted for 40 (56%), 27 (38%) and 16 (22%) cases of NKTCL, respectively. CD30 expression was significantly higher in large/anaplastic cell-predominant NKTCL than in small/medium cell-predominant cases. CD30-positive NKTCL showed better responses to non-anthracycline-based therapy. CD30-positive NKTCL with COV of 25% showed a lower rate of relapse. Moreover, in patients treated with non-anthracycline-based chemotherapy, CD30 positivity with COV of 5% was significantly and independently associated with longer overall survival. CD30 may be useful as a prognostic factor and therapeutic target in NKTCL.
authors.affiliation: Department of Pathology, Konkuk University School of Medicine , Seoul , South Korea.
authors.forename: Wook Youn
authors.initials: WY
authors.lastname: Kim
authors.forename: Soo Jeong
authors.initials: SJ
authors.lastname: Nam
authors.forename: Sehui
authors.initials: S
authors.lastname: Kim
authors.forename: Tae Min
authors.initials: TM
authors.lastname: Kim
authors.forename: Dae Seog
authors.initials: DS
authors.lastname: Heo
authors.forename: Chul-Woo
authors.initials: CW
authors.lastname: Kim
authors.forename: Yoon Kyung
authors.initials: YK
authors.lastname: Jeon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D059248:Chemoradiotherapy / Q000379:methods; D002648:Child; D018572:Disease-Free Survival; D004358:Drug Therapy / Q000379:methods; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D017730:Ki-1 Antigen / Q000096:biosynthesis*; D054391:Lymphoma, Extranodal NK-T-Cell / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D055611:Natural Killer T-Cells / Q000378:metabolism* / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017730:Ki-1 Antigen
keywords: CD30; EBV; brentuximab vedotin; extranodal NK/T-cell lymphoma; non-anthracycline-based chemotherapy; prognosis